ReviewMaternal health, neonatology and perinatology2026
Oxytocin discontinuation after the active phase of induced labour: an overview of systematic reviews.
Review in Maternal health, neonatology and perinatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo synthesize the available evidence on the effects of discontinuing oxytocin after the onset of the active phase of induced labour.
methodsAn overview of seven systematic reviews (SRs) and meta-analyses was conducted. Maternal and neonatal outcomes were extracted, and the methodological quality of reviews was assessed using AMSTAR. Primary study overlap among systematic reviews was quantified using the corrected covered area (CCA).
resultsDiscontinuation of oxytocin after the active phase was associated with a reduction in cesarean delivery in six SRs. Uterine tachysystole was significantly reduced across all SRs. Nonreassuring fetal heart rate (FHR) patterns were more frequent in the oxytocin continuation groups. Findings for postpartum hemorrhage were inconsistent. Neonatal outcomes, including Apgar score < 7 at 5 min, cord blood pH < 7.10, neonatal asphyxia, and NICU admission, showed no significant differences between groups. Discontinuation was also associated with a modest prolongation of the active phase. Using the AMSTAR tool, all SRs demonstrated high methodological quality (mean score 9.2; range 8-11). However, the seven systematic reviews were highly redundant, largely analyzing the same 15 unique primary RCTs (corrected covered area = 64.4%).
conclusionDiscontinuing oxytocin after the active phase of labour may reduce maternal complications, particularly uterine tachysystole, without compromising most neonatal outcomes. However, the certainty of the evidence is limited by heterogeneity in oxytocin protocols, substantial overlap among the included systematic reviews and their primary trials, and the relatively small number of unique randomized controlled trials. Further high-quality randomized controlled trials using standardized oxytocin regimens are needed to provide more definitive evidence. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.